Amorphous Nilotinib Composition for Stable Oral Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Nilotinib, a lipophilic compound, has low oral bioavailability, significant absorption variations due to food intake, and inter-subject variability, posing risks such as QT interval prolongation and sudden deaths.
Innovation Solution
A pharmaceutical composition comprising an amorphous solid dispersion of nilotinib with surfactants, non-ionic hydrophilic polymers, and optional adsorbents, which enhances bioavailability and reduces absorption variations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If nilotinib is administered in conventional crystalline form, then the formulation is simple and stable, but oral bioavailability is low and absorption varies significantly with food intake
Solution Approach 1:
The patent transforms nilotinib from crystalline to amorphous state, fundamentally changing the physical state parameter to improve solubility and bioavailability. The amorphous solid dispersion formulation uses nilotinib in an amorphous state dispersed in a hydrophilic polymer matrix, which prevents crystallization and maintains high solubility throughout the gastrointestinal tract, thereby achieving at least 2-fold higher bioavailability compared to conventional crystalline formulations
Solution Approach 2:
The patent creates a composite amorphous solid dispersion system combining nilotinib with hydrophilic polymers (such as HPMC, PVP, or PEG) and surfactants. This composite material approach allows the lipophilic nilotinib to be dispersed in a hydrophilic matrix, creating a formulation that maintains drug stability while dramatically improving wetting, dissolution, and absorption properties, reducing food effect variability to less than 50%
2Ease of operation
If nilotinib is taken with food, then absorption variability increases, but patient compliance may improve
Solution Approach 1:
The amorphous solid dispersion formulation creates a dynamic system that adapts to different gastrointestinal conditions. The formulation maintains drug solubility across varying pH and food conditions through the amorphous state and hydrophilic polymer matrix, allowing the drug to remain in solution regardless of food intake, thereby reducing absorption variability to less than 50% between fed and fasted states while permitting flexible dosing
Solution Approach 2:
The hydrophilic polymer matrix and surfactants act as intermediaries between the lipophilic nilotinib and the aqueous gastrointestinal environment. These intermediaries facilitate drug solubilization and maintenance in solution under varying physiological conditions, decoupling absorption consistency from food intake status and enabling patients to take the medication with or without food
3Reliability
If higher doses of nilotinib are administered to overcome low bioavailability, then therapeutic effect may improve, but QT interval prolongation risk increases
Solution Approach 1:
By changing the physical state from crystalline to amorphous, the formulation achieves at least 2-fold higher bioavailability, meaning lower doses can achieve the same therapeutic effect. This parameter change in physical state allows for dose reduction while maintaining therapeutic efficacy, thereby reducing the risk of QT interval prolongation and other dose-dependent adverse events
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition achieves at least 2-fold higher bioavailability and minimal variation (less than 50%) across fed and fasted states, improving safety and efficacy.
Implementation Method 1
an amorphous solid dispersion that comprises: nilotinib free base or a pharmaceutically acceptable salt thereof
Implementation Method 2
one or more surfactants, wherein the one or more surfactants is are selected from one or more polymeric non-ionic surfactants, and one or more phospholipids
Implementation Method 3
a non-ionic hydrophilic polymer
Data Source
AI summary
Provided are pharmaceutical compositions which include a mixture of a lipophilic active pharmaceutical ingredient such as nilotinib, a hydrophilic polymer, one or more surfactants, and optionally an adsorbent. Also described are methods for preparing and using such pharmaceutical compositions. In one aspect, disclosed herein is an amorphous solid dispersion comprising the active pharmaceutical ingredient.